Ameriprise’s Anika Therapeutics ANIK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$757K Sell
52,237
-1,003
-2% -$11.6K ﹤0.01% 3418
2025
Q4
$512K Buy
53,240
+20,251
+61% +$194K ﹤0.01% 3613
2025
Q3
$310K Sell
32,989
-8,373
-20% -$80K ﹤0.01% 3789
2025
Q2
$438K Buy
41,362
+1,820
+5% +$23K ﹤0.01% 3572
2025
Q1
$594K Sell
39,542
-6,551
-14% -$109K ﹤0.01% 3418
2024
Q4
$759K Buy
46,093
+20,663
+81% +$408K ﹤0.01% 3364
2024
Q3
$628K Sell
25,430
-5,891
-19% -$153K ﹤0.01% 3407
2024
Q2
$793K Sell
31,321
-8,203
-21% -$213K ﹤0.01% 3250
2024
Q1
$1M Sell
39,524
-83,571
-68% -$2.02M ﹤0.01% 3166
2023
Q4
$2.79M Sell
123,095
-121,418
-50% -$2.51M ﹤0.01% 2703
2023
Q3
$4.56M Sell
244,513
-48,052
-16% -$997K ﹤0.01% 2351
2023
Q2
$7.6M Buy
292,565
+84,364
+41% +$2.26M ﹤0.01% 2019
2023
Q1
$5.98M Buy
208,201
+26,258
+14% +$782K ﹤0.01% 2195
2022
Q4
$5.38M Sell
181,943
-9,417
-5% -$268K ﹤0.01% 2242
2022
Q3
$4.55M Sell
191,360
-21,593
-10% -$497K ﹤0.01% 2287
2022
Q2
$4.75M Sell
212,953
-4,928
-2% -$110K ﹤0.01% 2324
2022
Q1
$5.47M Sell
217,881
-769,767
-78% -$23.5M ﹤0.01% 2365
2021
Q4
$35.4M Sell
987,648
-7,309
-0.7% -$293K 0.01% 1010
2021
Q3
$42.3M Sell
994,957
-2,215
-0.2% -$91.2K 0.01% 848
2021
Q2
$43.2M Sell
997,172
-183
-0% -$7.79K 0.01% 873
2021
Q1
$40.7M Sell
997,355
-6,753
-0.7% -$256K 0.01% 861
2020
Q4
$45.4M Sell
1,004,108
-2,831
-0.3% -$107K 0.02% 779
2020
Q3
$35.6M Buy
1,006,939
+93,574
+10% +$3.38M 0.01% 779
2020
Q2
$34.5M Buy
913,365
+269,074
+42% +$8.87M 0.01% 766
2020
Q1
$18.6M Buy
644,291
+66,403
+11% +$2.69M 0.01% 976
2019
Q4
$30M Sell
577,888
-67,695
-10% -$3.93M 0.01% 935
2019
Q3
$35.4M Sell
645,583
-355,496
-36% -$18.3M 0.02% 814
2019
Q2
$40.7M Buy
1,001,079
+356,686
+55% +$13M 0.02% 773
2019
Q1
$19.5M Buy
644,393
+438,849
+214% +$15M 0.01% 1162
2018
Q4
$6.91M Buy
205,544
+4,707
+2% +$170K ﹤0.01% 1897
2018
Q3
$8.47M Buy
200,837
+2,401
+1% +$94.9K ﹤0.01% 2005
2018
Q2
$6.35M Sell
198,436
-146,311
-42% -$6.03M ﹤0.01% 2072
2018
Q1
$17.1M Buy
344,747
+228,253
+196% +$12.9M 0.01% 1237
2017
Q4
$6.28M Sell
116,494
-2,715
-2% -$150K ﹤0.01% 1967
2017
Q3
$6.91M Sell
119,209
-7,594
-6% -$397K ﹤0.01% 1843
2017
Q2
$6.26M Buy
126,803
+8,347
+7% +$384K ﹤0.01% 1907
2017
Q1
$5.15M Buy
118,456
+26,362
+29% +$1.26M ﹤0.01% 2027
2016
Q4
$4.51M Buy
92,094
+19,009
+26% +$879K ﹤0.01% 2123
2016
Q3
$3.5M Buy
73,085
+525
+0.7% +$25.9K ﹤0.01% 2245
2016
Q2
$3.89M Sell
72,560
-17,023
-19% -$802K ﹤0.01% 2131
2016
Q1
$4.01M Buy
89,583
+22,008
+33% +$893K ﹤0.01% 2111
2015
Q4
$2.58M Sell
67,575
-2,053
-3% -$78.5K ﹤0.01% 2452
2015
Q3
$2.22M Sell
69,628
-367
-0.5% -$12.8K ﹤0.01% 2560
2015
Q2
$2.31M Sell
69,995
-395
-0.6% -$14.1K ﹤0.01% 2659
2015
Q1
$2.9M Buy
70,390
+4,666
+7% +$189K ﹤0.01% 2399
2014
Q4
$2.68M Sell
65,724
-15,611
-19% -$610K ﹤0.01% 2417
2014
Q3
$2.98M Buy
81,335
+15,170
+23% +$656K ﹤0.01% 2330
2014
Q2
$3.06M Buy
66,165
+18,983
+40% +$844K ﹤0.01% 2344
2014
Q1
$1.94M Buy
47,182
+2,339
+5% +$86.9K ﹤0.01% 2496
2013
Q4
$1.71M Buy
44,843
+44,094
+5,887% +$1.36M ﹤0.01% 2508
2013
Q3
$18K Sell
749
-6,590
-90% -$148K ﹤0.01% 4486
2013
Q2
$126K Buy
+7,339
New +$106K ﹤0.01% 3287

Other funds holding ANIK

Ameriprise's ANIK Position: Q1 2026 in Review

Ameriprise reduced its Anika Therapeutics (ANIK) stake by 1.9% in Q1 2026, selling an estimated $11.6K and leaving 52,237 shares worth $757K. The position accounts for ﹤0.01% of the portfolio, ranked #3418.

Ameriprise first reported a position in ANIK in Q2 2013 and has held it in 52 quarters since. The position peaked at $45.4M in Q4 2020. 130 funds tracked by Wall St. Rank hold ANIK as of Q1 2026.

  • Ameriprise held 52,237 shares of Anika Therapeutics worth $757K as of Q1 2026.
  • Ameriprise sold 1,003 Anika Therapeutics shares in Q1 2026, an estimated $11.6K.
  • Anika Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #3418 holding.
  • Ameriprise first reported a position in Anika Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • Ameriprise's Anika Therapeutics position peaked at $45.4M in Q4 2020.
  • 130 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.